Analysis of MUC4 expression in the prostatic adenocarcinoma and its pathological implications
DOI:
https://doi.org/10.18203/2320-6012.ijrms20162955Keywords:
Muc-4 expression, Prostate cancer, ImmunohistochemistryAbstract
Background: Expression of various types of mucins has been documented in several malignancies and seems to play a sentinel role in some epithelial malignancies. MUC1 and MUC4 are two transmembrane mucins that are involved in cell signalling events that drive the proliferation of cells. Therefore, mucins may be important biomarkers for early diagnosis and targeted therapy due to their frequently altered expression pattern in carcinomas. The objective of the study was to determine the expression pattern of MUC-4 in prostate cancer and to correlate the expression with clinicopathological parameters.
Methods: Thirty cases of prostate carcinomas of different grades were selected from the case files of our institute for the study. Immunohistochemistry was done on all cases using monoclonal antibodies against MUC- 4 by the avidin biotin technique. The expression and pattern of staining were analyzed .Staining pattern in the adjacent benign areas were also noted.
Results: Our study showed that expression of MUC4 was considerably down regulated in prostate cancer tissues when compared to normal or benign prostatic tissue. Few cases of prostate cancer showed a moderate staining while majority cases of adjacent normal areas were moderate to strongly positivity.
Conclusions: The results of our study implies that MUC4 is down regulated in prostate cancer and this may be of significance for diagnostic application and tumor progression in prostate cancer. Since MUC4 is known to modulate HER2/ErbB2 signalling it may prospectively prove to be useful in prostate cancer therapy.
References
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer. 2013.
Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease Ninth ed: Elsevier. 2015.
Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India. Meta Gene. 2014;2:596-605.
Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, Russell PJ. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clinical & experimental metastasis. 2005;22(7):565-73.
Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clinical chemistry. 2011;57(10):1366-75.
Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nature reviews Cancer. 2004;4(1):45-60.
Hudson MJ, Stamp GW, Chaudhary KS, Hewitt R, Stubbs AP, Abel PD. Human MUC1 mucin: a potent glandular morphogen. The Journal of pathology. 2001;194(3):373-83.
Kufe DW. Mucins in cancer: function, prognosis and therapy. Nature reviews Cancer. 2009;9(12):874-85.
Saitou M, Goto M, Horinouchi M, Tamada S, Nagata K, Hamada T. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. Journal of clinical pathology. 2005;58(8):845-52.
Chaturvedi P, Singh AP, Batra SK. Structure, evolution, and biology of the MUC4 mucin. FASEB J. 2008;22(4):966-81.
Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth MA. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clinical cancer research: an official journal of the American Association for Cancer Research. 2001;7(12):4033-40.
Buisine MP, Devisme L, Copin MC, Durand-Reville M, Gosselin B, Aubert JP. Developmental mucin gene expression in the human respiratory tract. Am J Respir Cell Mol Biol. 1999;20(2):209-18.
Lopez-Ferrer A, Curull V, Barranco C, Garrido M, Lloreta J, Real FX. Mucins as differentiation
markers in bronchial epithelium. Squamous cell carcinoma and adenocarcinoma display similar expression patterns. Am J Respir Cell Mol Biol. 2001;24(1):22-9.
Singh AP, Chauhan SC, Bafna S, Johansson SL, Smith LM, Moniaux N. Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. The Prostate. 2006;66(4):421-9.
Davidson B, Baekelandt M, Shih Ie M. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol. 2007;35(12):756-60.
Hanaoka J, Kontani K, Sawai S, Ichinose M, Tezuka N, Inoue S. Analysis of MUC4 mucin expression in lung carcinoma cells and its immunogenicity. Cancer. 2001;92(8):2148-57.
Singh AP, Chaturvedi P, Batra SK. Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer research. 2007;67(2):433-6.
Tamada S, Shibahara H, Higashi M, Goto M, Batra SK, Imai K. MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006;12 (14 Pt 1):4257-64.
Tsutsumida H, Goto M, Kitajima S, Kubota I, Hirotsu Y, Wakimoto J. MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer. 2007;55(2):195-203.
Senapati S, Chaturvedi P, Sharma P, Venkatraman G, Meza JL, El-Rifai W. Deregulation of MUC4 in gastric adenocarcinoma: potential pathobiological implication in poorly differentiated non-signet ring cell type gastric cancer. British journal of cancer. 2008;99(6):949-56.
